Neurosense Therapeutics Ltd Stock Buy Hold or Sell Recommendation
| NRSNW Stock | USD 0.24 0.06 20.00% |
Assuming the 90 days horizon and your way above-average risk tolerance, our recommendation regarding NeuroSense Therapeutics Ltd is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell NeuroSense Therapeutics Ltd given historical horizon and risk tolerance towards NeuroSense Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for NeuroSense Therapeutics Ltd, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out NeuroSense Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide. Note, we conduct extensive research on individual companies such as NeuroSense and provide practical buy, sell, or hold advice based on investors' constraints. NeuroSense Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
NeuroSense |
Execute NeuroSense Therapeutics Buy or Sell Advice
The NeuroSense recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NeuroSense Therapeutics Ltd. Macroaxis does not own or have any residual interests in NeuroSense Therapeutics Ltd or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NeuroSense Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
NeuroSense Therapeutics Trading Alerts and Improvement Suggestions
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NeuroSense to Present Phase 2b ALS Treatment Trial Results at Major 2024 Symposium NRSN Stock News - StockTitan |
NeuroSense Therapeutics Returns Distribution Density
The distribution of NeuroSense Therapeutics' historical returns is an attempt to chart the uncertainty of NeuroSense Therapeutics' future price movements. The chart of the probability distribution of NeuroSense Therapeutics daily returns describes the distribution of returns around its average expected value. We use NeuroSense Therapeutics Ltd price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NeuroSense Therapeutics returns is essential to provide solid investment advice for NeuroSense Therapeutics.
| Mean Return | 3.03 | Value At Risk | -40 | Potential Upside | 52.94 | Standard Deviation | 23.99 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NeuroSense Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NeuroSense Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NeuroSense Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NeuroSense Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NeuroSense stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 3.12 | |
β | Beta against Dow Jones | -0.9 | |
σ | Overall volatility | 185.38 | |
Ir | Information ratio | 0.12 |
NeuroSense Therapeutics Volatility Alert
NeuroSense Therapeutics Ltd is showing large volatility of returns over the selected time horizon. NeuroSense Therapeutics Ltd is a potential penny stock. Although NeuroSense Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in NeuroSense Therapeutics Ltd. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on NeuroSense instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.NeuroSense Therapeutics Fundamentals Vs Peers
Comparing NeuroSense Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NeuroSense Therapeutics' direct or indirect competition across all of the common fundamentals between NeuroSense Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NeuroSense Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NeuroSense Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NeuroSense Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NeuroSense Therapeutics to competition |
| Fundamentals | NeuroSense Therapeutics | Peer Average |
| Return On Equity | -4.95 | -0.31 |
| Return On Asset | -1.51 | -0.14 |
| Number Of Shares Shorted | 2.21 K | 4.71 M |
| EBITDA | (10.63 M) | 3.9 B |
| Net Income | (11.28 M) | 570.98 M |
| Cash And Equivalents | 994 K | 2.7 B |
| Cash Per Share | 0.13 X | 5.01 X |
| Total Debt | 142 K | 5.32 B |
| Current Ratio | 8.08 X | 2.16 X |
| Book Value Per Share | (0.09) X | 1.93 K |
| Cash Flow From Operations | (8.45 M) | 971.22 M |
| Earnings Per Share | (0.94) X | 3.12 X |
| Number Of Employees | 18 | 18.84 K |
| Beta | 1.57 | -0.15 |
| Total Asset | 3.18 M | 29.47 B |
| Retained Earnings | (32.07 M) | 9.33 B |
| Working Capital | (543 K) | 1.48 B |
| Net Asset | 3.18 M |
NeuroSense Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NeuroSense . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NeuroSense Therapeutics Buy or Sell Advice
When is the right time to buy or sell NeuroSense Therapeutics Ltd? Buying financial instruments such as NeuroSense Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NeuroSense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.